0001372514-23-000034.txt : 20230307 0001372514-23-000034.hdr.sgml : 20230307 20230307201450 ACCESSION NUMBER: 0001372514-23-000034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230303 FILED AS OF DATE: 20230307 DATE AS OF CHANGE: 20230307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daniels Eric Joseph CENTRAL INDEX KEY: 0001892943 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 23714566 MAIL ADDRESS: STREET 1: C/O EYEGATE PHARMACEUTICALS INC. STREET 2: 271 WAVERLY OAKS RD., STE 108 CITY: WALTHAM STATE: MA ZIP: 02452 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 781-788-8869 MAIL ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 4 1 wf-form4_167823807843002.xml FORM 4 X0306 4 2023-03-03 0 0001372514 KIORA PHARMACEUTICALS INC KPRX 0001892943 Daniels Eric Joseph 332 ENCINITAS BLVD., SUITE 102 ENCINITAS CA 92024 0 1 0 0 Chief Development Officer Common Stock 2023-03-03 4 A 0 15600 0 A 25838 D Stock Option (right to buy) 3.83 2023-03-03 4 A 0 10400 0 A 2033-03-03 Common Stock 10400.0 10400 D Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of March 3, 2024, March 3, 2025 and March 3, 2026, subject to the reporting person's continuous service through each such vesting date. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 3, 2024, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. /s/ Robert A. Petitt, Attorney-in-Fact 2023-03-08